Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | CYP19A1 | P11511 | 10/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | CYP11B1 | P15538 | 7/20 | 0.54 |
| ▸ | CYP11B2 | P19099 | 7/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.48 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL77675 | 0.84 | ALDH1A1 (0.64) | ALDH1A1CYP19A1LMNASMN1; SMN2CYP11B1 | |
| SCHEMBL9527373 | 0.81 | ALDH1A1 (0.67) | ALDH1A1CYP19A1LMNASMN1; SMN2CYP11B1 | |
| SCHEMBL9523331 | 0.81 | ALDH1A1 (0.67) | ALDH1A1CYP19A1LMNASMN1; SMN2CYP11B1 | |
| SCHEMBL10581105 | 0.81 | ALDH1A1 (0.63) | ALDH1A1CYP19A1LMNASMN1; SMN2CYP11B1 | |
| SCHEMBL9523915 | 0.81 | ALDH1A1 (0.82) | ALDH1A1CYP19A1LMNASMN1; SMN2CYP11B1 | |
| SCHEMBL9664212 | 0.80 | CYP19A1 (0.60) | ALDH1A1CYP19A1LMNASMN1; SMN2CYP11B1 | |
| SCHEMBL79024 | 0.79 | CYP11B1 (0.67) | CYP19A1CYP11B1CYP11B2CYP2A6CYP2B6 | |
| SCHEMBL9665076 | 0.79 | ALDH1A1 (0.61) | ALDH1A1CYP19A1LMNASMN1; SMN2CYP11B1 | |
| SCHEMBL10579958 | 0.78 | ALDH1A1 (0.67) | ALDH1A1CYP19A1LMNASMN1; SMN2CYP11B1 | |
| SCHEMBL9663781 | 0.78 | ALDH1A1 (0.54) | ALDH1A1CYP19A1LMNASMN1; SMN2CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129396-B2 | 2-[1H-benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides as kinase inhibitors | TELIK, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20100081653-A1 | 2-[1H-Benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides as kinase inhibitors | TELIK, INC. | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081653-A1 | 2-[1H-Benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides as kinase inhibitors | MAP3K2, MAP4K2, MAP3K12 | ALDH1A1 1651/4885CYP19A1 3796/4885LMNA 3563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.